A double blind randomized placebo control trial of levetiracetam in Tourette syndrome

Movement Disorders

Volumn 22, Issue 12, 2007, Pages 1764-1770

  Smith Hicks, Constance L ^a   Bridges, Dana D ^a   Paynter, Nina P ^b   Singer, Harvey S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Levetiracetam; Tourette syndrome

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; PLACEBO;

ADOLESCENT; AGGRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FATIGUE; FEMALE; GILLES DE LA TOURETTE SYNDROME; HOPELESSNESS; HUMAN; HYPERKINESIA; INSOMNIA; MALE; NERVOUSNESS; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; VERBAL HOSTILITY;

ADOLESCENT; ANTICONVULSANTS; CHILD; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PIRACETAM; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOURETTE SYNDROME;

EID: 35348969794     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21615     Document Type: Article

References (24)

1. Singer HS. Tourette's syndrome: from behaviour to biology. Lancet Neurol 2005;4:149-159.
2. Singer HS, Minzer K. Neurobiology of Tourette's syndrome: concepts of neuroanatomic localization and neurochemical abnormalities. Brain Dev 2003;25 (Suppl 1):S70-S84.
3. Harris K, Singer HS. Tic disorders: neural circuits, neurochemistry, and neuroimmunology. J Child Neurol 2006;21:678-689.
4. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654-1660.
5. Poulain P, Margineanu DG. Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neuropharmacology 2002;42:346-352.
6. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002;136:659-672.
7. Awaad Y, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 2005;20:714-718.
8. Awaad YM, A; Minarik S. Long-term follow-up use of levetiracetam to treat tics in children. Ann Neurol 2005;58:S112.
9. Peterson BS, Cohen DJ. The treatment of Tourette's syndrome: multimodal, developmental intervention. J Clin Psychiatry 1998;59 (Suppl 1):62-72; discussion 73-64.
10. Dure LSt, DeWolfe J. Treatment of tics. Adv Neurol 2006;99:191-196.
11. Wheless JW, Ng YT. Levetiracetam in refractory pediatric epilepsy. J Child Neurol 2002;17:413-415.
12. Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566-573.
13. Pelham WE, Jr, Carlson C, Sams SE, Vallano G, Dixon MJ, Hoza B. Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom. J Consult Clin Psychol 1993; 61:506-515.
14. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. Pediatrics 1991;87:519-531.
15. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 1997;36:844-852.
16. March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry 1997;36:554-565.
17. Kovacs M. The Children's Depression, Inventory (CDI). Psychopharmacol Bull 1985;21:995-998.
18. The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol 1993;50:1013-1016.
19. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60:1130-1135.
20. Senn S. The design and analysis of cross-over trials, 2nd ed. Chinchester: Wiley; 2002.
21. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
22. Piazzini A, Chifari R, Canevini MP, Turner K, Fontana SP, Canger R. Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Res 2006;68:181-188.
23. Walkup JT, Rosenberg LA, Brown J, Singer HS. The validity of instruments measuring tic severity in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1992;31:472-477.
24. Leckman JF, Peterson BS. The pathogenesis of Tourette's syndrome: epigenetic factors active in early CNS development. Biol Psychiatry 1993;34:425-427.